Verrica Pharmaceuticals
Price & Volume
Stats
See moreOpen | $4.20 |
Previous Close | $4.31 |
Day Range | $4.12-$4.21 |
52W Range | $3.81-$17.50 |
Market Cap | $40.7M |
Shares Short | 165,518 |
Financials
See moreRevenue (12 Mos) | $14.7M |
Revenue Growth (YoY) | 145.4% |
Gross Profit (12 Mos) | $5M |
Diluted EPS | -$7.74 |
News
See moreYahoo Finance • 6 days ago
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Yahoo Finance • last month
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
Yahoo Finance • 2 months ago
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Yahoo Finance • 3 months ago
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales
About
CEO | Dr. Jayson M. Rieger M.B.A., Ph.D. |
Address | 44 West Gay Street, West Chester, PA, United States, 19380 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 71 |
